- Revenue for the quarter up 2% to $3.6M for Q3 2024 compared to $3.5M for Q3 2023.
- Loss from operations was $(0.4)M
for Q3 2024, compared to $(0.4)M for Q3 2023.
- Net Loss for Q3 2024 was $(0.7)M
compared to $(0.4)M Q3 2023.
- Adjusted EBITDA(1) for Q3 2024 was $nil, compared to
$0.1M for Q3 2023.
- Adjusted EBITDA Margin(1) of (1)% in Q3 2024
compared to 3% in Q3 2023.
- ARR(2) of $11.4M as of
September 30, 2024, a decrease of 2%
over the same date in 2023.
MONTREAL, Nov. 15,
2024 /CNW/ - Carebook Technologies Inc.
("Carebook" or the "Company") (TSXV: CRBK), a leading
Canadian provider of innovative digital health solutions today
announced its results for the quarter ended September 30, 2024.
"We showed lower revenue growth during the quarter ending
September 2024 as additional revenue
from new and existing customers compensated just enough to replace
churned customers" commented Michael
Peters, Carebook CEO. "Despite unusual expenses in the
quarter we were able to maintain our margins as we prepare for
another phase of growth. We will continue managing cost with an
objective of minimizing cash burn and increasing our profit
margins."
_______________________________
|
1 EBITDA and
Adjusted EBITDA are non-IFRS financial measures, and Adjusted
EBITDA Margin is a non-IFRS financial ratio, in each case without a
standardized meaning under IFRS and which may not be comparable to
similar measures or ratios used by other issuers. Please refer to
the sections "Cautionary Note Regarding Non-IFRS Measures, non-IFRS
Ratios and Key Performance Indicators", "Non-IFRS Measures and
Non-IFRS Ratios" and "Non-IFRS Measures and Reconciliation of
Non-IFRS Measures EBITDA and Adjusted EBITDA" for the definitions
of such non-IFRS financial measures and ratio, an explanation of
the usefulness of such non-IFRS financial measures and ratio, and a
reconciliation of non-IFRS financial measures to the most directly
comparable IFRS financial measure.
2 Annual
Recurring Revenue or ARR is a key performance indicator.
Please refer to the sections "Cautionary Note Regarding Non-IFRS
Measures, non-IFRS Ratios and Key Performance Indicators" and "Key
Performance Indicators" below for the definition of ARR, as well as
an explanation of the usefulness of such key performance indicator
to the Company.
|
Q3 2024 Highlights
Revenue
Revenue for the quarter ended September
30, 2024 was $3.6M compared to
$3.5M for the quarter ended
September 30, 2023, an increase of
2%. Revenue in the quarter ended September
30, 2024, was contributed 64% from the employer vertical and
36% from our key customer in the pharmacy vertical.
Loss from Operations and Net Loss
Loss from operations for the quarter ended September 30, 2024, was $(0.4)M compared to $(0.4)M for the same period in 2023. The small
increase in operating expenses when compared to the quarter ended
September 30, 2023 was partially due
to the recognition of a bad debt expense during the quarter ended
September 30, 2024.
Net loss was $(0.7)M for the
quarter ended September 30, 2024,
compared to a loss of $(0.4)M for the
quarter ended September 30, 2023. The
$0.3M increase in expenses is due in
part to the recognition of a bad debt expense and a lower income
tax recovery during the quarter ended September 30, 2024.
Adjusted EBITDA
Adjusted EBITDA(1) for the quarter ended September 30, 2024 was $nil compared to
$0.1M for the quarter ended
September 30, 2023, representing a
decrease of $(0.1)M. The
corresponding Adjusted EBITDA Margin(1) for the quarter
ended September 30, 2024 was (1)%
compared to 3% in the quarter ended September 30, 2023.
Annual Recurring Revenue
ARR(2) was -$11.4M as
at September 30, 2024, a decrease of $(0.2)M, or (2)%, compared to an
ARR(2) of $11.6M as at
September 30, 2023. Of the -$11.4M of ARR(2) reported, 60%
originated from clients outside of Canada.
Renewal and Amendment of Credit Facilities
Effective September 30, 2024, the
Company entered into an eighth amendment to its existing senior
credit facilities ("Credit Facilities") with a leading
Canadian Schedule I bank (the "Lender"). Under the eighth
amendment, the maturity date of the Credit Facilities was extended
to October 31, 2024.
Effective October 31st, 2024, the
Company entered into a ninth amendment to its Credit Facilities.
Under the ninth amendment, the maturity date of the Credit
Facilities was extended to October 31,
2025, and the size of the revolving facility was increased
to $3.5M. Effective October 31, 2024, the applicable interest rate on
the revolving facility was decreased to prime plus 4.0% and the
applicable interest rate on the term loan facility was decreased to
prime plus 4.25%.
The Credit Facilities are subject to a new financial covenant,
where the Company must maintain a minimum monthly adjusted EBITDA
(as defined under the ninth amendment). The Credit Facilities
continue to be secured by a first-ranking security interest in all
of the present and future property and assets of the Company and
certain of its subsidiaries.
Frankfurt Stock Exchange Delisting
During the fourth quarter, the Company decided to request a
delisting of its common shares on the Frankfurt Stock Exchange. The
delisting process has commenced and the last trading day of the
common shares, under the symbol PPM1 on the Frankfurt Stock
Exchange, is expected to be on or around December 20, 2024.
Financial Outlook
Carebook's financial outlook continues to be generally positive
for 2024. The Company is poised to achieve revenue
growth on an annual basis, while effectively managing its costs and
delivering sustained growth in cashflows. Carebook's organic
growth and efficient cost management initiatives will allow the
Company to continue to successfully execute on its strategy.
Carebook is expecting to maintain strong performance on an annual
basis for 2024 for the entire Company as a whole and although
actual results may differ, we believe Carebook is positioned to
deliver Adjusted EBITDA(1) break even or better in
fiscal 2024. To complement its organic growth strategy, Carebook
will continue to seek out accretive acquisitions and partnerships
that improve the accessibility, quality, and functionality of its
comprehensive solutions, surrounding ecosystem, and supporting
services. Carebook has adopted a disciplined approach towards
exploring strategic M&A opportunities in order to grow its
reach in other markets and offer new services to its customer base,
while maintaining a focus on its organic growth. This financial
outlook is fully qualified and based on a number of assumptions and
subject to a number of risks described under the headings
"Financial Outlook Assumptions" and "Notice Regarding
Forward-Looking Statements" of this press release.
Conference Call Details
A conference call will be held at 8:30 AM Eastern
on November 15, 2024 to discuss Carebook's year end
financial results. Participants may join the Company's conference
call by using the following information:
Conference Call
Details
|
|
Date
|
Friday, November 15,
2024
|
Time:
|
8:30 a.m. Eastern
Time
|
Local:
|
1-437-900-0527
|
North American Toll
Free:
|
1-888-510-2154
|
RapidConnect
URL:
|
Click here
|
Webcast URL:
|
Click here
|
|
|
Conference
Replay
|
|
Local:
|
1-289-819-1450
|
North American Toll
Free:
|
1-888-660-6345
|
Entry Code:
|
24051 #
|
Expiration
Date:
|
11/22/2024
|
Carebook's interim condensed consolidated financial statements
and accompanying notes, and Management's Discussion and Analysis
for the quarter ended September 30, 2024 are available on
the Company's website at www.carebook.com and on SEDAR+
at www.sedarplus.ca.
Cautionary Note Regarding Non-IFRS Measures, non-IFRS Ratios
and Key Performance Indicators
This press release makes reference to certain non-IFRS measures
and key performance indicators. These measures are not standardized
financial measures under IFRS as issued by the IASB and do not have
a standardized meaning prescribed by IFRS and are therefore
unlikely to be comparable to similar measures presented by other
companies. Rather, these measures are provided as additional
information to complement those IFRS measures by providing further
understanding of our results of operations from management's
perspective. Accordingly, these measures should not be considered
in isolation nor as a substitute for analysis of our financial
information reported under IFRS. We use non-IFRS measures,
including "EBITDA" and "Adjusted EBITDA" and non-IFRS ratios
including "Adjusted EBITDA Margin". This press release also makes
reference to "Annual Recurring Revenue" or "ARR", which is a key
performance indicator used in our industry. These non-IFRS
measures, non-IFRS ratios and key performance indicators are used
to provide investors with supplemental measures of our operating
performance and liquidity and thus highlight trends in our business
that may not otherwise be apparent when relying solely on IFRS
measures. The Company also believes that securities analysts,
investors, and other interested parties frequently use non-IFRS
measures, non-IFRS ratios and key performance indicators in the
evaluation of issuers. The Company's management also uses non-IFRS
measures, non-IFRS ratios and key performance indicators in order
to facilitate operating performance comparisons from period to
period, to prepare annual operating budgets and forecasts, and to
determine components of management and executive compensation. The
key performance indicators used by the Company may be calculated in
a manner different than similar key performance indicators used by
other companies.
Non-IFRS Measures and Non-IFRS Ratios
"Adjusted EBITDA" is defined as EBITDA adjusted for
non-recurring M&A and other transaction costs, certain
non-recurring costs (or savings), share-based compensation, foreign
exchange loss (gain), intangible asset and goodwill impairment,
changes in fair value of warrants or changes in fair value of
contingent consideration. Adjusted EBITDA provides management with
a useful supplemental measure in evaluating the performance of our
operations and provides better transparency into our results of
operations. Adjusted EBITDA indicates our ability to generate
profit from our operations prior to considering our financing
decisions and costs of consuming intangible and capital assets.
"EBITDA" is defined as net income or loss before income tax
expenses, finance costs and depreciation and amortization.
"Adjusted EBITDA Margin" is calculated as Adjusted EBITDA
divided by revenue for the relevant period.
Key Performance Indicators
"Annual Recurring Revenue" or "ARR" represents contracted
software and services revenues that are expected to have a duration
of more than one year, and is equal to the annualized value of
contracted recurring revenue from all clients on our platforms at
the date being measured. Contracted recurring revenue is revenue
generated from clients who are, as of the date being measured,
party to contracts with Carebook that are contributing to revenue
in the calendar month of the date being measured, and also include
revenue from clients who are, as of the date being measured, party
to contracts with Carebook that are to contribute to revenue within
a year of the date being measured. ARR provides a consolidated
measure by which we can monitor the longer-term trends in our
business.
Non-IFRS Measures and Reconciliation of Non-IFRS Measures
EBITDA and Adjusted EBITDA
(ooo's)
|
|
|
THREE
MONTHS
ENDED
September 30, 2024
|
|
|
THREE
MONTHS
ENDED
September 30, 2023
|
|
|
NINE
MONTHS
ENDED
September 30, 2024
|
|
|
NINE
MONTHS
ENDED
September 30, 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$
|
(671)
|
|
$
|
(390)
|
|
$
|
(1,688)
|
|
$
|
(1,540)
|
Add:
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization and
depreciation expense
|
$
|
369
|
|
$
|
387
|
|
$
|
1,108
|
|
$
|
1,206
|
Finance
costs
|
|
$
|
397
|
|
$
|
362
|
|
$
|
1,169
|
|
$
|
1,113
|
Other income
(1)
|
|
$
|
(3)
|
|
$
|
(4)
|
|
$
|
(22)
|
|
$
|
(215)
|
Income Tax expense
(recovery)
|
|
$
|
(162)
|
|
$
|
(320)
|
|
$
|
(486)
|
|
$
|
(960)
|
Impairment
(2)
|
|
$
|
-
|
|
$
|
-
|
|
$
|
-
|
|
$
|
178
|
EBITDA
(3)
|
|
$
|
(70)
|
|
$
|
35
|
|
$
|
81
|
|
$
|
(218)
|
Add:
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-Based
compensation
|
|
$
|
36
|
|
$
|
98
|
|
$
|
104
|
|
$
|
156
|
Additional One-Time
Costs (Savings) (4)
|
$
|
(13)
|
|
$
|
(23)
|
|
$
|
(199)
|
|
$
|
(535)
|
Adjusted EBITDA
(3)
|
|
$
|
(47)
|
|
$
|
110
|
|
$
|
(14)
|
|
$
|
(597)
|
(1)
|
Other income includes a
gain following the initial recognition of the net investment from
the Montreal office sublease for the nine months ending September
30, 2023.
|
(2)
|
Impairment on disposal
of leasehold improvements from Carebook subleasing the Montreal
office.
|
(3)
|
Non-IFRS financial
measures without a standardized definition under IFRS, which may
not be comparable to similar measures used by other issuers. Refer
to the Section "Non-IFRS Measures and Non-IFRS Ratios" for an
explanation of the composition and usefulness of these non-IFRS
financial measures.
|
(4)
|
Additional One-Time
Costs (Savings) relate to investment tax credits and grants
received from the Quebec government and Prompt, a trust agency of
the Ministry of Economy, Innovation and Energy research group in
Québec.
|
About Carebook Technologies
Carebook's digital health platform empowers its clients and more
than 5.0 million members to take control of their health journey.
During 2021, the Company completed the acquisitions of InfoTech
Inc. ("InfoTech"), a global leader in health and
productivity risk management, and CoreHealth Technologies Inc.
("CoreHealth"), owner of an industry-leading wellness
platform. In combination, these companies create a comprehensive
digital health platform that includes both assessment tools and the
technology to deliver complementary solutions. Carebook's shares
trade on the TSXV under the symbol "CRBK".
www.carebook.com
For further information contact:
Carebook Investor Relations Contact:
Olivier Giner, CFO
Email : ir@carebook.com
Telephone: (450) 977-0709
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this news release.
Financial Outlook Assumptions
Our financial outlook is based on a number of assumptions,
including assumptions related to inflation, changes in interest
rates, consumer spending, foreign exchange rates and other
macroeconomic conditions; our major revenue streams remaining in
line with our expectations; customers adopting our solutions at an
average contract value at or above that of our planned levels; our
ability to price our products in line with our expectations and to
achieve suitable margins; our ability to achieve success in the
continued expansion of our product lines and solutions; continued
success in additional product adoption and user base expansion
throughout our customer base; our ability to derive the benefits we
expect from the acquisitions we have completed; our ability to
attract and retain key personnel required to achieve our plans; our
expectations regarding the costs, timing and impact of our cost
reduction initiatives; our ability to manage customer churn and
churn rates remaining at planned levels. Our financial outlook does
not give effect to the potential impact of acquisitions that may be
announced or closed after the date hereof. Our financial outlook,
including the various underlying assumptions, constitutes
forward-looking information and should be read in conjunction with
the cautionary notice on forward-looking statements below. Many
factors may cause our actual results, level of activity,
performance or achievements to differ materially from those
expressed or implied by such forward-looking information.
Notice Regarding Forward-Looking Statements:
This release includes forward-looking information and
forward-looking statements within the meaning of Canadian
securities laws regarding Carebook, its subsidiaries and their
business. Often, but not always, forward-looking information can be
identified by the use of words such as "plans", "is expected",
"expects", "scheduled", "intends", "contemplates", "anticipates",
"believes", "proposes" or variations (including negative
variations) of such words and phrases, or state that certain
actions, events or results "may", "could", "would", "might" or
"will" be taken, occur or be achieved. Forward-looking information
in this release include statements with respect to revenue, our
2024 full year outlook, the Company's growth strategy, management's
expectations regarding revenue growth and cost management, contract
generation and the overall value of recently signed contracts and
the Company's path to profitability. Such statements are based on
the current expectations of the management of Carebook and are
based on assumptions and subject to risks and uncertainties.
Although the management of Carebook believes that the assumptions
underlying these statements are reasonable, they may prove to be
incorrect, and undue reliance should not be placed on such
forward-looking statements. The forward-looking statements reflect
the Company's current views with respect to future events based on
currently available information and are inherently subject to risks
and uncertainties. The forward-looking events and circumstances
discussed in this release may not occur by certain specified dates
or at all and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the Company,
including economic factors, management's ability to manage and to
operate the business of Carebook, management's ability to identify
attractive M&A opportunities, management's ability to
successfully integrate the Company's completed acquisitions and to
realize the synergies of such acquisitions, management's ability to
successfully complete product studies, the equity markets generally
and risks associated with growth and competition, management's
ability to achieve profitability for the Company, as well as the
risk factors identified in the Company's management's discussion
and analysis for the year ended December 31,
2023, a copy of which can be found on SEDAR+ under the
Company's profile at www.sedarplus.ca. Although Carebook has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward-looking statement can be guaranteed. Except
as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Carebook does not undertake any obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.
SOURCE Carebook Technologies Inc.